AR062234A1 - Derivados de ester de nitrato de piperidinas sustituidas y metodos de preparacion - Google Patents

Derivados de ester de nitrato de piperidinas sustituidas y metodos de preparacion

Info

Publication number
AR062234A1
AR062234A1 ARP070103476A ARP070103476A AR062234A1 AR 062234 A1 AR062234 A1 AR 062234A1 AR P070103476 A ARP070103476 A AR P070103476A AR P070103476 A ARP070103476 A AR P070103476A AR 062234 A1 AR062234 A1 AR 062234A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
alq
alkylamino
pyridyl
Prior art date
Application number
ARP070103476A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR062234A1 publication Critical patent/AR062234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente se refiere a un proceso para su preparacion, y el uso de estos compuestos como un agente terapéutico para enfermedades cardiovasculares, en particular en casos de presion arterial elevada y dano vascular y orgánico concomitante con la presion arterial elevada. Reivindicacion 1: Compuesto de la formula general (1) donde R1 es arilo o heterociclilo, en particular benzimidazolilo, benzo[1,3]dioxolilo, benzofuranilo, benzooxazolilo, benzotiazolilo, benzo[b]tienilo, quinazolinilo, quinolilo, quinoxalinilo, 2H-cromenilo, 3,4-dihidro-2H-benzo[1,4]oxazinilo, dihidro-3H-benzo-[1,4]oxazinilo, dihidro-2H-benzo[1,4]tiazinilo, 1a,7b-dihidro-1H-ciclopropa[c]cromenilo, 2,3-dihidro-1H-indolilo, dihidro-1H-pirido[2,3-b][1,4]oxazinilo, imidazo[1,2-a]piridilo, imidazo[1,5-a]piridilo, indazolilo, indolilo, isobenzofuranilo, isoquinolilo, [1,5]naftiridilo, fenilo, ftalazinilo, piridilo, pirimidinilo, 1H-pirrolo[2,3-b]piridilo, 1H-pirrolo[2,3-c]piridilo, 1H-pirrolo[3,2-b]piridilo, tetrahidro-quinolilo, tetrahidroquinoxalinilo, 1,1a,2,7b-tetrahidro-ciclopropa[c]cromenilo, tetrahidroimidazo[1,2-a]-piridilo, tetrahidroimidazo[1,5-a]piridilo, tetrahidro-isoquinolilo, [1,2,3]triazolo[1,5-a]piridilo o [1,2,4]triazolo[4,3- a]piridilo, que están sustituidos con 1-4 sustituyentes acil-alcoxi C1-8-alcoxi C1-8, acil-alcoxi C1-8-alquilo C1-8, (N-acil)-alcoxi C1-8-alquilamino C1-8, alcanoilo C1-8, alcoxi C1-8, aIcoxi C1-8-alcanoilo C1-8, alcoxi C1-8-alcoxi C1-8, alcoxi C1-8- alcoxi C1-8-alquilo C1-8, alcoxi C1-8-alquilo C1-8, (N-alcoxi C1-8)-alquilamino C1-8-carbonil-alcoxi C1-8, (N-alcoxi C1-8)-alquilamino C1-8-carbonil-alquilo C1-8, alcoxi C1-8-alquilcarbamoilo C1-8, alcoxi C1-8-alquilcarbonilo C1-8, alcoxi C1-8- alquilcarbonil-amino C1-8, 1-alcoxi C1-8-alquilheterociclilo C1-8, alcoxiaminocarbonil C1-8-alcoxi C1-8, alcoxiamino C1-8-carbonil-alquilo C1-8, alcoxicarbonilo C1-8, alcoxi C1-8-carbonil-alcoxi C1-8, alcoxicarbonil C1-8-alquilo C1-8, alcoxicarbonilamino C1-8-alcoxi C1-8, alcoxicarbonil C1-8-amino-alquilo C1-8, alquilo C1-8, (N-alquilo C1-8)-alcoxiC1-8-alquilcarbamoilo C1-8, (N-alquilo C1-8)-alcoxi C1-8-alquilcarbonil-amino C1-8, (N-alquilo C1-8)-alcoxicarbonilamino C1-8, (N- alquilo C1-8)-alquilcarbonilamino C1-8-alcoxi C1-8, (N-alquil C1-8)-alquilcarbonilamino C1-8-alquilo C1-8, (N-alquilo C1-8)-alquilsulfonilamino C1-8-alcoxi C1-8, (N-alquilo C1-8)-alquilsulfonilamino C1-8-alquilo C1-8, alquilamidinilo C1-8, alquilamino C1-8-alcoxi C1-8, di-alquilamino C1-8-alcoxi C1-8, alquilamino C1-8-alquilo C1-8, di-alquilamino C1-8-alquilo C1-8, alquilamino C1-8-carbonil-alcoxi C1-8, di-alquilamino C1-8-carbonil-alcoxi C1-8, alquilamino C1-8-carbonil-alcoxi C1-8- alquilo C1-8, alquilamino C1-8-carbonil-alquilo C1-8, di-alquilamino C1-8-carbonil-alquilo C1-8, alquilamino C1-8-carbonilamino-alcoxi C1-8, alquilamino C1-8-carbonilamino-alquilo C1-8, alquilcarbonilamino C1-8, alquilcarbonilamino C1-8-alcoxi C1-8, alquilcarbonilamino C1-8-alquilo C1-8, alquilcarboniloxi C1-8-alcoxi C1-8, alquilcarboniloxi C1-8-alquilo C1-8, alquilsulfonilo C1-8, alquilsulfonil C1-8-alcoxi C1-8, alquilsulfonil C1-8-alquilo C1-8, alquil C1-8-sulfonilamino-alcoxi C1-8, alquilsulfonilamino C1-8-alquilo C1-8, amino opcionalmente N-mono- o N,N-di-alquilado C1-8, aril-alcoxi C0-8, aril-alquilo C0-8, carbamoil alcoxi C0-8 opcionalmente N-mono- o N,N-di-alquilado C1-8, carbamoilalquilo C0-8 opcionalmente N-mono- o N,N- di-alquilado C1-8, carboxi-alcoxi C1-8, carboxi-alcoxi C1-8-alquilo C1-8, carboxi-alquilo C1-8, ciano, ciano-alcoxi C1-8, ciano-alquilo C1-8, cicloalquil C3-8-alcoxi C1-8, cicloalquil C3-8-alquilo C1-8, cicloalquilcarbonilamino C3-8-alcoxi C1-8, cicloalquilcarbonilamino C3-8-alquilo C1-8, O,N-dimetilhidroxiamino-alquilo C1-8, halogeno, halo-alcoxi C1-8, halo-alquilo C1-8, heterociclil-alcoxi C0-8, heterociclil-alquilo C0-8, heterociclilcarbonilo, hidroxi-alcoxi C1-8-alcoxi C1-8, hidroxi- alcoxi C1-8-alquilo C1-8, hidroxi-alquilo C1-8, O-metiloximil-alquilo C1-8, oxido u oxo; R2 es alqueniloxi C2-8-alcoxi C1-8, alqueniloxi C2-8-alquilo C1-8, alcoxi C1-8, alcoxi C1-8-alcoxi C1-8, alcoxi C1-8-alcoxi C1-8-alquilo C1-8 sustituido de modo opcional con halogeno, alcoxi C1-8-alquilo C1-8, alcoxi C1-8-alquilamino C1-8-alcoxi C1-8, alcoxi C1-8-alquilamino C1-8-alquilo C1-8, alcoxi C1-8-alquilsulfanil C1-8-alcoxi C1-8, alcoxi C1-8-alquilsulfanil-C1-8-alquilo C1-8, alcoxi C1-8-alquil-C0-8- cicloalquil-C3-8-alcoxi C0-8-alquilo C1-8, alquilo C1-8, alquil C1-8-sulfanil-alcoxi C1-8, alquilsulfanil C 1-8-alcoxi C1-8-alcoxi C1-8, alquilsulfanil C1-8-alcoxi C1-8-alquilo C1-8, alquilsulfanil C1-8-alquilo C1-8, alquilsulfonil C1-8-alcoxi C1-8- alcoxi C1-8, alquilsulfonil C1-8-alcoxi C1-8-alquilo C1-8, aril-alcoxi C0-8-alcoxi C1-8, aril-alcoxi C0-8-alquilo C1-8, ariloxi, cicloalquil-C3-8-alcoxi C0-8-alcoxi C1-8, cicloalquil C3-8-alcoxi C0-8-alcoxi C1-8-alquilo C1-8, cicloalquil C3-8-alcoxi C0-8-alquilo C1-8, heterociclil-alcoxi C0-8-alcoxi C1-8, heterociclil-alcoxi C0-8-alquilo C1-8 o heterocicliloxi; R3 es halogeno, R4 es acilo, alquenilo C2-8, alquilo C1-8, aril-alquilo C1-8 o hidrogeno; X es -alq-, -O-alq-, -alq-O-, -O-alq-O-, -S- alq-, -alq-S-, -alq-NR4-, -NR4-alq-, -C(O)-NR4, -alq-C(O)-NR4-, -O-alq-C(O)-NR4-, -C(O)-NR4-alq-, -alq-C(O)-NR4-alq-, NR4-C(O)-, -alq-NR4-C(O)-, -NR4-C(O)-alq-, -alq-NR4-C(O)-alq-, -O-alq-C(O)NR4-, -O-alq-NR4-C(O)-, -S(O)2-NR4-, -alq-S(O)2-NR4-, - S(O)2-NR4-alq-, -alq-S(O)2-NR4-alq-, -NR4-S(O)2-, -alq-NR4-S(O)2-, -NR4-S(O)2-alq- o -alq-NR4-S(O)2-alq-, donde alq indica alquileno C1-8 que puede estar sustituido de modo opcional con halogeno; Y es a) -alq-, -alq-O-alq-, -alq-NR4-alq-, -alq-C(O)- alq-,alq-C(O)-NR4-alq-, -alq-C(O)-alq-NR4-alq-, -alq-NR4-C(O)-alq-, -alq-NR4-alq-C(O)-alq-, no sustituido o sustituido con heterociclilo y/o halogeno y/o hidroxi y/o alcoxi, donde alq indica alquileno C1-8 lineal o ramificado; o b) si p = 0, es adicionalmente i) una union, ii) -alq-O, -alq-NR4-, -alq-C(O)-, alq-NR4-C(O)-alq-O-, no sustituido o sustituido con heterociclilo y/o halogeno y/o hidroxi y/o alcoxi donde alq indica alquileno C1-8 lineal o ramificado; Z0 es igual a -U-Z1- donde Z, es -C(O)-O-, -O-C(O)O-, -C(O)-NR7-C(O) u -O-C(O)-NR7-C(O)-, donde R7 es como se definio a continuacion; U es un radical bivalente que tiene el siguiente significado: a) -alquileno C1-8, de preferencia alquileno C1-8 que está sustituido de modo opcional con uno o más de los sustituyentes seleccionados del grupo formado por: halogeno, hidroxi, -ONO2 o To, donde To es -OC(O)-(alquilo C1-8)-ONO2 u -O-(alquilo C1-8)-ONO2; -cicloalquileno C3-8, donde el anillo está sustituido de modo opcional con cadenas laterales T, donde T es alquilo C1-8; b) un grupo de formula (2) donde v es un numero entero de 0 a 20, y v1 es un numero entero de 1 a 20; c) un grupo de formula (3) donde v es un numero entero de 0 a 20, y v1 es un numero entero de 1 a 20; d) un grupo de formula (4) donde: v1 es como se definio antes y v2 es un numero entero de 0 a 2; Z2 = -O-C(O)- o -C(O)-O- y R5 es H o CH3; e) un grupo de formula (5) donde: v1, v2, R5 y Z2 son como se definio antes; U1 es -CH2-CH2- o -CH=CH- (CH2)v2-; f) un grupo de formula (6) donde: v1 y R5 son como se definio antes, R6 es H o -C(O)CH3; g) grupo de formulas (7) donde Z3 es -O-, o -S-, v3 es un numero entero de 1 a 6, de preferencia de 1 a 4, R5 es como se definio antes; o h) un grupo de formula (8) donde: v4 es un numero entero de 0 a 10; v5 es un numero entero de 1 a 10; R7, R8, R9, R10 son iguales o diferentes, y son H o alquilo C1-4; U2 es un anillo heterocíclico saturado, no saturado o aromático de 5 o 6 miembros, que contiene uno o más heteroátomos seleccionados de nitrogeno, oxigeno y azufre, y de preferencia se seleccionan del grupo de formulas (9); m es 0, 1 o 2; n es 0 o 1; p es 0 o 1; q es 0 o 1; donde si p es = 0, q es = 1 y si p es =1, q es = 0, y sus sales, de preferencia sus sales aceptables para uso farmacéutico.
ARP070103476A 2006-08-08 2007-08-07 Derivados de ester de nitrato de piperidinas sustituidas y metodos de preparacion AR062234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH12792006 2006-08-08

Publications (1)

Publication Number Publication Date
AR062234A1 true AR062234A1 (es) 2008-10-22

Family

ID=38683550

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103476A AR062234A1 (es) 2006-08-08 2007-08-07 Derivados de ester de nitrato de piperidinas sustituidas y metodos de preparacion

Country Status (15)

Country Link
US (1) US20090325947A1 (es)
EP (1) EP2049514B1 (es)
JP (1) JP2010500327A (es)
KR (1) KR20090061000A (es)
CN (1) CN101501020A (es)
AR (1) AR062234A1 (es)
AT (1) ATE496904T1 (es)
AU (1) AU2007283631A1 (es)
BR (1) BRPI0715412A2 (es)
CA (1) CA2660538A1 (es)
DE (1) DE602007012260D1 (es)
MX (1) MX2009001404A (es)
RU (1) RU2009107891A (es)
TW (1) TW200821303A (es)
WO (1) WO2008017685A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074450A2 (en) * 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CN101910131B (zh) 2007-11-16 2014-04-23 里格尔药品股份有限公司 甲酰胺、磺酰胺和胺化合物及其使用方法
WO2009076631A1 (en) 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2708866A1 (en) 2007-12-19 2009-06-25 Hiroyuki Nakahira Bicyclic heterocyclic derivative
JP5658138B2 (ja) 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
US8658639B2 (en) 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
EP2560634A1 (en) * 2010-04-23 2013-02-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
IT1243367B (it) * 1990-07-26 1994-06-10 Italfarmaco Spa Derivati acidi benzoici sostituiti ad attivita' cardiovascolare
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
AU2004260830B2 (en) * 2003-07-31 2010-04-29 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases
RU2374228C2 (ru) * 2003-11-26 2009-11-27 Новартис Аг Производные 4-фенилпиперидина в качестве ингибиторов ренина
AR053406A1 (es) * 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
TW200722424A (en) * 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
BRPI0609534A2 (pt) * 2005-03-31 2010-04-13 Speedel Experimenta Ag piperidinas 3,4,5-substituìdas
TW200833687A (en) * 2005-03-31 2008-08-16 Speedel Experimenta Ag Substituted piperidines
TW200804359A (en) * 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols

Also Published As

Publication number Publication date
AU2007283631A1 (en) 2008-02-14
MX2009001404A (es) 2009-05-13
DE602007012260D1 (de) 2011-03-10
EP2049514A1 (en) 2009-04-22
JP2010500327A (ja) 2010-01-07
CA2660538A1 (en) 2008-02-14
KR20090061000A (ko) 2009-06-15
WO2008017685A1 (en) 2008-02-14
TW200821303A (en) 2008-05-16
EP2049514B1 (en) 2011-01-26
US20090325947A1 (en) 2009-12-31
BRPI0715412A2 (pt) 2013-07-02
ATE496904T1 (de) 2011-02-15
RU2009107891A (ru) 2010-09-20
CN101501020A (zh) 2009-08-05

Similar Documents

Publication Publication Date Title
AR062234A1 (es) Derivados de ester de nitrato de piperidinas sustituidas y metodos de preparacion
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
CO6190523A2 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
ES2562218T3 (es) Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas
AR001021A1 (es) Derivados de pirazol-4-il-benzoilo, procedimiento para prepararlos, composiciones herbicidas formuladas con dichos derivados y procedimiento paracombatir el crecimiento de plantas indeseables con aplicacion de dichos derivados.
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
UY25682A1 (es) Procedimiento para preparar derivados de quinolin-2-ona alquinilsustituidos útiles como agentes anticancerosos entre otras acciones terapéuticas
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR044005A1 (es) Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden
ES2162466T3 (es) Derivados de 1,2,4-triazolo(4,3-b)pirido(3,2-d)piridazina y composiciones farmaceuticas que los contienen.
CO5550444A2 (es) Pirazolpirimidinas como agentes terapeuticos
UY27457A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
CO5680443A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos
AR064258A1 (es) Inhibidores macrociclicos del virus de hepatitis c
UY28805A1 (es) Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso par tratar la diabetes y trastornos relacionados
PA8783601A1 (es) Derivados de piperidina/piperazina
AR035777A1 (es) Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
PE20080378A1 (es) Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa
AR062405A1 (es) Derivados de isoindol

Legal Events

Date Code Title Description
FB Suspension of granting procedure